Order:
  1.  14
    A Threshold of Significant Harm (F)or a Viable Alternative Therapeutic Option?Jo Bridgeman - 2018 - Journal of Medical Ethics 44 (7):466-470.
    This article critically examines the legal arguments presented on behalf of Charlie Gard’s parents, Connie Yates and Chris Gard, based on a threshold test of significant harm for intervention into the decisions made jointly by holders of parental responsibility. It argues that the legal basis of the argument, from the case of Ashya King, was tenuous. It sought to introduce different categories of cases concerning children’s medical treatment when, despite the inevitable factual distinctions between individual cases, the duty of the (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  2. Because We Care? The Medical Treatment of Children.Jo Bridgeman - 1998 - In Sally Sheldon & Michael Thomson (eds.), Feminist Perspectives on Health Care Law. Cavendish. pp. 97--114.
     
    Export citation  
     
    Bookmark   2 citations  
  3. Children with Severe Disabilities and Their Families : Re-Examining Private Responsibilities and Public Obligations From a Caring Perspective.Jo Bridgeman - 2008 - In Michael D. A. Freeman (ed.), Law and Bioethics / Edited by Michael Freeman. Oxford University Press.
     
    Export citation  
     
    Bookmark  
  4.  16
    Editorial: Critically Ill Children and Best Interests.Jo Bridgeman - 2010 - Clinical Ethics 5 (4):184-187.
  5.  20
    Clare Williams, Mothers, Young People andChronic Illness.Jo Bridgeman - 2003 - Feminist Legal Studies 11 (2):213-216.
  6.  5
    ‘Exceptional’ Women, Healthcare Consumers and the Inevitability of Caring.Jo Bridgeman - 2007 - Feminist Legal Studies 15 (2):235-245.
    In Rogers, the Court of Appeal held that the decision of Swindon N.H.S. Primary Care Trust to refuse to fund Herceptin for the treatment of Ann Rogers against breast cancer was irrational. The P.C.T. maintained that their decision was not resource driven but based on the fact that Herceptin was, at that time, not licensed by the European Medicines Agency (E.M.E.A.) for use in early stage breast cancer. Yet it was prepared to fund its use in ‹exceptional circumstances’ which could (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  7.  3
    Children’s Medical Treatment Decision-Making: Reform or Review?Jo Bridgeman - 2021 - Clinical Ethics 16 (3):183-188.
    This article considers proposals to reform the law in response to recent high profile cases concerning the medical treatment of children, currently before Parliament in the Access to Palliative Care and Treatment of Children Bill 2019–21. It considers the proposed procedural change, to introduce a requirement for mediation before court proceedings, and argues that dispute resolution processes should be a matter of good practice rather than enshrined in law. It argues that the proposed substantive change to determination of best interests (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark